| Randomized trial of thymectomy in myasthenia gravis GI Wolfe, HJ Kaminski, IB Aban, G Minisman, HC Kuo, A Marx, P Ströbel, ... New England Journal of Medicine 375 (6), 511-522, 2016 | 891 | 2016 |
| Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial PH Gordon, DH Moore, RG Miller, JM Florence, JL Verheijde, C Doorish, ... The Lancet Neurology 6 (12), 1045-1053, 2007 | 756 | 2007 |
| Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind … JF Howard, K Utsugisawa, M Benatar, H Murai, RJ Barohn, I Illa, S Jacob, ... The Lancet Neurology 16 (12), 976-986, 2017 | 586 | 2017 |
| 224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14–16 October 2016 Y Allenbach, AL Mammen, O Benveniste, W Stenzel, A Amato, A Aussey, ... Neuromuscular disorders 28 (1), 87-99, 2018 | 432 | 2018 |
| Whole-genome analysis of sporadic amyotrophic lateral sclerosis T Dunckley, MJ Huentelman, DW Craig, JV Pearson, S Szelinger, ... New England journal of medicine 357 (8), 775-788, 2007 | 313 | 2007 |
| Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial AM Wills, J Hubbard, EA Macklin, J Glass, R Tandan, EP Simpson, ... The Lancet 383 (9934), 2065-2072, 2014 | 288 | 2014 |
| Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial JF Howard, V Bril, T Vu, C Karam, S Peric, T Margania, H Murai, ... The Lancet Neurology 20 (7), 526-536, 2021 | 277 | 2021 |
| An overview of polymyositis and dermatomyositis AR Findlay, NA Goyal, T Mozaffar Muscle & nerve 51 (5), 638-656, 2015 | 260 | 2015 |
| A randomized, double‐blind, placebo‐controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis JF Howard Jr, RJ Barohn, GR Cutter, M Freimer, VC Juel, T Mozaffar, ... Muscle & nerve 48 (1), 76-84, 2013 | 238 | 2013 |
| A review of spasticity treatments: pharmacological and interventional approaches EY Chang, N Ghosh, D Yanni, S Lee, D Alexandru, T Mozaffar Critical Reviews™ in Physical and Rehabilitation Medicine 25 (1-2), 2013 | 219 | 2013 |
| PIP2 binding residues of Kir2.1 are common targets of mutations causing Andersen syndrome MR Donaldson, JL Jensen, M Tristani–Firouzi, R Tawil, S Bendahhou, ... Neurology 60 (11), 1811-1816, 2003 | 217 | 2003 |
| Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres T Mozaffar, A Pestronk Journal of Neurology, Neurosurgery & Psychiatry 68 (4), 472-478, 2000 | 212 | 2000 |
| Clinical findings in MuSK‐antibody positive myasthenia gravis: a US experience M Pasnoor, GI Wolfe, S Nations, J Trivedi, RJ Barohn, L Herbelin, ... Muscle & Nerve: Official Journal of the American Association of …, 2010 | 208 | 2010 |
| Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis JF Howard Jr, V Bril, TM Burns, R Mantegazza, M Bilinska, A Szczudlik, ... Neurology 92 (23), e2661-e2673, 2019 | 197 | 2019 |
| Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis S Muppidi, K Utsugisawa, M Benatar, H Murai, RJ Barohn, I Illa, S Jacob, ... Muscle & nerve 60 (1), 14-24, 2019 | 186 | 2019 |
| Paraneoplastic necrotizing myopathy: clinical and pathologic features MI Levin, T Mozaffar, M Taher Al-Lozi, A Pestronk Neurology 50 (3), 764-767, 1998 | 182 | 1998 |
| Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial GI Wolfe, HJ Kaminski, IB Aban, G Minisman, HC Kuo, A Marx, P Ströbel, ... The Lancet Neurology 18 (3), 259-268, 2019 | 177 | 2019 |
| Chronic nerve compression induces local demyelination and remyelination in a rat model of carpal tunnel syndrome R Gupta, K Rowshan, T Chao, T Mozaffar, O Steward Experimental neurology 187 (2), 500-508, 2004 | 154 | 2004 |
| Genetic landscape and novel disease mechanisms from a large LGMD cohort of 4656 patients BRR Nallamilli, S Chakravorty, A Kesari, A Tanner, A Ankala, T Schneider, ... Annals of clinical and translational neurology 5 (12), 1574-1587, 2018 | 150 | 2018 |
| Diagnostic criteria for late‐onset (childhood and adult) Pompe disease American Association of Neuromuscular & Electrodiagnostic Medicine Muscle & nerve 40 (1), 149-160, 2009 | 149 | 2009 |
